Browsing by Author "Abdel-Aziz A.K."

Now showing 1 - 2 of 2

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside
(Elsevier Ltd, 2019) Abdel-Aziz A.K.; Saadeldin M.K.; D'Amico P.; Orecchioni S.; Bertolini F.; Curigliano G.; Minucci S.; Department of Experimental Oncology; IEO; European Institute of Oncology IRCCS; Milan; Italy; Department of Pharmacology and Toxicology; Faculty of Pharmacy; Ain Shams University; Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; 6th October City; Cairo; Egypt; Division of Early Drug Development for Innovative Therapies; IEO; European Institute of Oncology IRCCS; Milan; Italy; Laboratory of Hematology-Oncology; IEO; European Institute of Oncology IRCCS; Milan; Italy; Department of Oncology and Hemato-Oncology; University of Milano; Milan; Italy; Department of Biosciences; University of Milan; Milan; Italy
The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy. 2019 Elsevier Ltd
Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: A case control study
(Public Library of Science, 2018) Saadeldin M.K.; Elshaer S.S.; Emara I.A.; Maged M.; Abdel-Aziz A.K.; Department of Biochemistry; Faculty of Pharmacy (Girls); Al-Azhar University; Cairo; Egypt; Department of Biochemistry; National Institute of Diabetes and Endocrinology (NIDE); Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; 6th October City; Cairo; Egypt; Department of Experimental Oncology; European Institute of Oncology; Milan; Italy
Diabetes mellitus represents a major independent risk factor for developing fatal cardiovascular diseases (CVDs) presumably through accelerating atherosclerosis; the underlying cause of most CVDs. Notably, this relative risk is reported to be higher in women than men. Endeavors directed towards identifying novel reliable predictive biomarkers are immensely thereby urged to improve the long-term outcome in these diabetic female patients. Sclerostin (SOST) is a Wnt signaling antagonist whereas irisin is a muscle-derived factor released after exercising which enhances browning of white adipose tissue. Emerging lines of evidence hint at potential crosstalk between them and CVDs. The present study aimed to assess the serum levels of SOST and irisin in Egyptian type 2 diabetic (T2DM) female patients with and without atherosclerosis and explore the possible relationship between both markers and other studied parameters among the studied cohorts. In this case-control study, 69 female subjects were enrolled; 39 type 2 diabetes patients with atherosclerosis (T2DM+ATHR), 22 type 2 diabetes patients without atherosclerosis (T2DM-ATHR) and 8 healthy controls. Their serum levels of SOST and irisin were assessed using ELISA. Significant increase in SOST levels were found in T2DM+ATHR compared to T2DM-ATHR and control (259.9 �17.98 vs. 165.8�13.12 and 142.0�13.31 pg/mL respectively, P0.001). Conversely, irisin levels were significantly lower in T2DM+ATHR (P0.001) and T2DM-ATHR (P0.01) compared to the control group (32.91�2.545 and 58.55�13.19 vs. 473.6�112.7 pg/ mL). Interestingly, significant correlations between the levels of SOST and both irisin and fasting blood glucose were noticed in T2DM+ATHR group (r = 0.3754 and 0.3381 respectively, P0.05). In conclusion, to the best of our knowledge, this study is the first to demonstrate the correlation between SOST and irisin levels in atherosclerotic T2DM female patients implying their potential implication in diabetic cardiovascular pathophysiology and supporting their use as reliable diagnostic/prognostic biomarkers for monitoring and preventing CVDs progression of T2DM female patients. � 2018 Saadeldin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.